1. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. (23rd August 2018) Authors: Staehler, M; Motzer, R J; George, D J; Pandha, H S; Donskov, F; Escudier, B; Pantuck, A J; Patel, A; DeAnnuntis, L; Bhattacharyya, H; Ramaswamy, K; Zanotti, G; Lin, X; Lechuga, M; Serfass, L; Paty, J; Ravaud, A Journal: Annals of oncology Issue: Volume 29:Number 10(2018) Page Start: 2098 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 881PCorrelations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial. (23rd October 2018) Authors: George, D J; Pantuck, A J; Figlin, R; Escudier, B; Halabi, S; Casey, M; Lin, X; Serfass, L; Lechuga Frean, M J; Ravaud, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗